Pay in 4 interest-free payments of $5.43 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Insurance coverage varies widely and often depends on whether the drug is prescribed for its FDA-approved indication, diabetes or weight loss
& Devlin, J
The Key Takeaways: Most common: Nausea (43%), manageable with dietary changes and timing Unique: Dysesthesia (20.9%), mild tingling sensations, not seen with Wegovy/Mounjaro Timeline: Worst during dose escalation (weeks 116), significant improvement after Discontinuation: 18.2% in TRIUMPH-4, 11.3% in TRIUMPH-1 the general obesity population tolerates it better than the osteoarthritis cohort Reversible: Stopping medication reverses side effects For most people with obesity especially severe obesity the 28.328.7% weight loss and associated health benefits outweigh the temporary discomfort during the first few months
However, improper usesuch as increasing the dosage too quicklycan reduce its effectiveness and lead to negative side effects
Treatment decisions should be made by patients and their healthcare providers. To land on the banned list, a substance has to satisfy two of three criteria: The potential to enhance sport performance
US$ 21.72
US$ 27.74
US$ 25.65
US$ 27.96
